1. Eva Bianconi, Allison Piovesan, Federica Facchin, Alina Beraudi, Raffaella Casadei, Flavia Frabetti, Lorenza Vitale, Maria Chiara Pelleri, Simone Tassani, Francesco Piva, Soledad Perez-Amodio, Pierluigi Strippoli & Silvia Canaider (2013) “An estimation of the number of cells in the human body.” Annals of Human Biology, 40:6, 463-471, DOI: 10.3109/03014460.2013.807878
  2. Madrigal, Alexis (2009, September 9). “Humans have made, found or used over 50 million unique chemicals.” Retrieved from
  3. Olcott, H. S. & Emerson, O. H. (1937). “Antioxidants and the autoxidation of fats.” IX. “The antioxidant properties of the tocopherols.” Journal of the American Chemical Society,59:1008–1009.
  4. Serbinova E, Kagan V, Han D, Packer L. “Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol.” Free Radical Biology & Medicine, 1991;10(5):263-75.
  5. Xia W, Mo H. “Potential of tocotrienols in the prevention and therapy of Alzheimer’s disease.” Journal of Nutritional Biochemistry, 2016;31:1-9. Epub 2016/05/03.
  6. Mangialasche F, Kivipelto M, Mecocci P, Rizzuto D, Palmer K, Winblad B, et al. “High plasma levels of vitamin E forms and reduced Alzheimer’s disease risk in advanced age.” Journal of Alzheimer’s Disease, JAD. 2010;20(4):1029-37. Epub 2010/04/24.
  7. Mangialasche F, Xu W, Kivipelto M, Costanzi E, Ercolani S, Pigliautile M, et al. “Tocopherols and tocotrienols plasma levels are associated with cognitive impairment.” Neurobiology of Aging, 2012;33(10):2282-90. Epub 2011/12/24.
  8. Mangialasche F, Westman E, Kivipelto M, Muehlboeck JS, Cecchetti R, Baglioni M, et al. “Classification and prediction of clinical diagnosis of Alzheimer’s disease based on MRI and plasma measures of alpha-/gamma-tocotrienols and gamma-tocopherol.” Journal of Internal Medicine, 2013. Epub 2013/01/25.
  9. Mangialasche F, Solomon A, Kareholt I, Hooshmand B, Cecchetti R, Fratiglioni L, et al. “Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults.” Experimental Gerontology, 2013;48(12):1428-35. Epub 2013/10/12.
  10. Chin, K.Y., et al. “The Effects of Tocotrienol and Lovastatin Co-Supplementation on Bone Dynamic Histomorphometry and Bone Morphogenetic Protein-2 Expression in Rats with Estrogen Deficiency.” Nutrients, 2017. 9(2).
  11. Chin, K.Y., et al. “The Effects of Annatto Tocotrienol on Bone Biomechanical Strength and Bone Calcium Content in an Animal Model of Osteoporosis Due to Testosterone Deficiency.” Nutrients, 2016. 8(12).
  12. Shen, C.L., et al. “Tocotrienol supplementation suppressed bone resorption and oxidative stress in postmenopausal osteopenic women: a 12-week randomized double-blinded placebo-controlled trial.Osteoporos International, 2018.
  13. Qureshi, A.A., et al. “Impact of delta-tocotrienol on inflammatory biomarkers and oxidative stress in hypercholesterolemic subjects.Journal of Clinical & Experimental Cardiology, 2015. 6(4): p. 1000367.
  14. Qureshi AA, Khan DA, Mahjabeen W, Qureshi N. “Dose-dependent modulation of lipid parameters, cytokines, and RNA by delta-tocotrienol in hypercholesterolemic subjects restricted to AHA Step-1 diet.” British Journal of Medicine and Medical Research, 2015;6(4):351-66.
  15. Qureshi AA, Khan DA, Mahjabeen W, Papasian CJ, Qureshi N. “Nutritional supplement-5 with a combination of proteasome inhibitors (resveratrol, quercetin, delta-tocotrienol) modulate age-associated biomarkers and cardiovascular lipid parameters in human subjects.” Journal of Clinical & Experimental Cardiology. 2013;4(3):1-14.
  16. Qureshi AA, Khan DA, Mahjabeen W, Papasian CJ, Qureshi N (2012) “Suppression of nitric oxide production and cardiovascular risk factors in healthy seniors and hypercholesterolemic subjects by a combination of polyphenols and vitamins. Journal of Clinical & Experimental Cardiology, S5:008. doi:10.4172/2155-9880.S5-008
  17. Pearce BC, Parker RA, Deason ME, Qureshi AA, Wright JJ. “Hypocholesterolemic activity of synthetic and natural tocotrienols.” Journal of Medicinal Chemistry, 1992;35:3595-606.
  18. Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJ. “Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.” Journal of Biological Chemistry, 1993;268:11230-8.
  19. Song BL, DeBose-Boyd RA. “Insig-dependent ubiquitination and degradation of 3-hydroxy-3-methylglutaryl coenzyme a reductase stimulated by delta- and gamma-tocotrienols.” Journal of Biological Chemistry, 2006. 281:25054-61.
  20. Zaiden N, Yap WN, Ong S, Xu CH, Teo VH, Chang CP, et al. “Gamma delta tocotrienols reduce hepatic triglyceride synthesis and VLDL secretion.” Journal of Atherosclerosis and Thrombosis. 2010;17(10):1019-32.
  21. O’Byrne D, Grundy S, Packer L, Devaraj S, Baldenius K, Hoppe PP, et al. Studies of LDL oxidation following alpha-, gamma-, or delta-tocotrienyl acetate supplementation of hypercholesterolemic humans. Free Radical Biology & Medicine, 2000;29(9):834-45.
  22. Carr AC, Zhu BZ, Frei B. “Potential antiatherogenic mechanisms of ascorbate (vitamin C) and alpha-tocopherol (vitamin E).” Circ Res. 2000;87(5):349-54. Epub 2000/09/02.
  23. Wong, W.Y., et al.Anti-inflammatory gamma- and delta-tocotrienols improve cardiovascular, liver and metabolic function in diet-induced obese rats.” European Journal of Nutrition, 2017. 56(1): p. 133-150.
  24. Allen L, Ramalingam L, Menikdiwela K, Scoggin S, Shen CL, Tomison MD, et al. “Effects of delta-tocotrienol on obesity-related adipocyte hypertrophy, inflammation and hepatic steatosis in high-fat-fed mice.” Journal of Nutritional Biochemistry, 2017;48:128-37. Epub 2017/08/22.
  25. Buckner T, Fan R, Kim Y, Kim J, Chung S. Annatto Tocotrienol Attenuates NLRP3 “Inflammasome Activation in Macrophages.” Current Developments in Nutrition, 2017;1(6):e000760. Epub 2018/06/30.
  26. Shibata A, Kawakami Y, Kimura T, Miyazawa T, Nakagawa K. “Alpha-Tocopherol Attenuates the Triglyceride- and Cholesterol-Lowering Effects of Rice Bran Tocotrienol in Rats Fed a Western Diet.” Journal of Agricultural and Food Chemistry, 2016;64(26):5361-6. Epub 2016/06/14.
  27. Le, M., Devaki, P., Ha, N., Jun, D., Te, H., Cheung, R. and Nguyen, M. (2017). Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLOS. Available from:
  28. Estes, C., Razavi, H., Loomba, R., Younossi, Z. and Sanyal, A. (2018). “Modeling the Epidemic of Nonalcoholic Fatty Liver Disease Demonstrates an Exponential Increase in Burden of Disease.” Hepatology, 67(1).
  29. Pervez, M.A., et al. “Effects of Delta-tocotrienol Supplementation on Liver Enzymes, Inflammation, Oxidative stress and Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease.” Turkish Journal of Gastroenterology, 2018. 29(2): p. 170-176.
  30. Fang F, Kang Z, Wong C. “Vitamin E tocotrienols improve insulin sensitivity through activating peroxisome proliferator-activated receptors.” Molecular Nutrition and Food Research, October, 2009 at Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou Science City, Guangzhou, P. R. China.
  31. Elson, C.E. “Suppression of mevalonate pathway activities by dietary isoprenoids: protective roles in cancer and cardiovascular disease.” Journal of Nutrition, 1995. 125(6 Suppl): p. 1666S-1672S.
  32. Miyazawa, T., et al. “Anti-angiogenic function of tocotrienol.” Asia Pacific Journal of Clinical Nutrition, 2008. 17 Suppl 1: p. 253-6.
  33. Nakagawa, K., et al. “DNA chip analysis of comprehensive food function: inhibition of angiogenesis and telomerase activity with unsaturated vitamin E, tocotrienol.” Biofactors, 2004. 21(1-4): p. 5-10.
  34. McIntyre BS, Briski KP, Gapor A, Sylvester PW. “Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells.” Proceedings of the Society of Experimental Biology and Medicine, 2000;224(4):292-301.
  35. Khallouki F, de Medina P, Caze-Subra S, Bystricky K, Balaguer P, Poirot M, et al. “Molecular and Biochemical Analysis of the Estrogenic and Proliferative Properties of Vitamin E Compounds.” Frontiers in Oncology, 2015;5:287. Epub 2016/01/19.
  36. Mo H, Elson CE. “Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention.” Experimental Biology and Medicine, 2004(229):567-85.
  37. Hindler K, Cleeland CS, Rivera E, Collard CD. “The role of statins in cancer therapy.” The Oncologist, 2006;11(3):306-15. Epub 2006/03/22.
  38. Montagnani Marelli M, Marzagalli M, Moretti RM, Beretta G, Casati L, Comitato R, et al. “Vitamin E delta-tocotrienol triggers endoplasmic reticulum stress-mediated apoptosis in human melanoma cells.” Scientific Reports, 2016;6:30502. Epub 2016/07/28.
  39. Jiang Q. “Natural forms of vitamin E and metabolites-regulation of cancer cell death and underlying mechanisms.” IUBMB Life. 2019;71(4):495-506. Epub 2018/12/15.
  40. Yang C, Jiang Q. “Vitamin E delta-tocotrienol inhibits TNF-alpha-stimulated NF-kappaB activation by up-regulation of anti-inflammatory A20 via modulation of sphingolipid including elevation of intracellular dihydroceramides.” Journal of Nutritional Biochemistry, 2019;64:101-9. Epub 2018/11/25.
  41. Qureshi AA, Zuvanich EG, Khan DA, Mushtaq S, Silswal N, Qureshi N. “Proteasome inhibitors modulate anticancer and anti-proliferative properties via NF-kB signaling, and ubiquitin-proteasome pathways in cancer cell lines of different organs.” Lipids in Health and Disease, 2018;17(1):62. Epub 2018/04/03.
  42. Nesaretnam K, Meganathan P. “Tocotrienols: inflammation and cancer.” Annals of the New York Academy of Scientists, 2011;1229(1):18-22.
  43. He L, Mo H, Hadisusilo S, Qureshi AA, Elson CE. “Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo.” Journal of Nutrition, 1997;127(5):668-74.
  44. Fernandes NV, Guntipalli PK, Mo H. “d-delta-Tocotrienol-mediated cell cycle arrest and apoptosis in human melanoma cells.” Anticancer Research, 2010;30(12):4937-44. Epub 2010/12/29.
  45. Luk SU, Yap WN, Chiu YT, Lee DT, Ma S, Lee TK, et al. “Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population.” Int J Cancer. 2011;128(9):2182-91.
  46. Kaneko S, Sato C, Shiozawa N, Sato A, Sato H, Virgona N, et al. “Suppressive Effect of Delta-Tocotrienol on Hypoxia Adaptation of Prostate Cancer Stem-like Cells.” Anticancer research. 2018;38(3):1391-9. Epub 2018/03/02.
  47. Gopalan A, Yu W, Sanders BG, Kline K. “Eliminating drug resistant breast cancer stem-like cells with combination of simvastatin and gamma-tocotrienol.” Cancer Lett. 2013;328(2):285-96. Epub 2012/10/16.
  48. Xiong A, Yu W, Tiwary R, Sanders BG, Kline K. “Distinct roles of different forms of vitamin E in DHA-induced apoptosis in triple-negative breast cancer cells.” Mol Nutr Food Res. 2012;56(6):923-34. Epub 2012/06/19.
  49. Husain K, Centeno BA, Coppola D, Trevino J, Sebti SM, Malafa MP. “delta-Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis.” Oncotarget. 2017;8(19):31554-67. Epub 2017/04/14.
  50. Marzagalli M, Moretti RM, Messi E, Marelli MM, Fontana F, Anastasia A, et al. “Targeting melanoma stem cells with the Vitamin E derivative delta-tocotrienol.” Scientific reports. 2018;8(1):587. Epub 2018/01/14.
  51. Thomsen CB, Andersen RF, Steffensen KD, Adimi P, Jakobsen, A. “Delta tocotrienol in recurrent ovarian cancer. A phase II trial.” Pharmacological Research, 2019;141:392-6. Epub 2019/01/15.
  52. Chin, K.Y. and S. Ima-Nirwana, “Effects of annatto-derived tocotrienol supplementation on osteoporosis induced by testosterone deficiency in rats.” Clinical Interventions in Aging, 2014. 9: p. 1247-59.
  53. Chin, K.Y. and S. Ima-Nirwana, “The biological effects of tocotrienol on bone: a review on evidence from rodent models.” Drug Design, Development and Therapy, 2015. 9: p. 2049-61.
  54. Shen, C.L., et al. “Tocotrienols for bone health: a translational approach.” Annals of the New York Academy of Scientists, 2017. 1401(1): p. 150-165.
  55. Shen CL, Mo H, Yang S, Wang S, Felton CK, Tomison MD, et al. “Safety and efficacy of tocotrienol supplementation for bone health in postmenopausal women: protocol for a dose-response double-blinded placebo-controlled randomised trial.” BMJ Open. 2016;6(12):e012572. Epub 2016/12/25.
  56. Shen CL, Wang S, Yang S, Tomison MD, Abbasi M, Hao L, et al. “A 12-week evaluation of annatto tocotrienol supplementation for postmenopausal women: safety, quality of life, body composition, physical activity, and nutrient intake.” BMC Complementary and Alternative Medicine, 2018;18(1):198. Epub 2018/06/30.
  57. Yu SG, Thomas AM, Gapor A, Tan B, Qureshi N, Qureshi AA. “Dose-response impact of various tocotrienols on serum lipid parameters in 5-week-old female chickens.” Lipids. 2006;41(5):453-61.
  58. Y. Qureshi AA, Pearce BC, Nor RM, Gapor A, Peterson DM, Elson CE. “Dietary alpha-tocopherol attenuates the impact of gamma-tocotrienol on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in chickens.” J Nutr. 1996;126(2):389-94.
  59. Rink C, Christoforidis G, Khanna S, Peterson L, Patel Y, Abduljalil A, et al. “Tocotrienol vitamin E protects against preclinical canine ischemic stroke by inducing arteriogenesis. Journal of cerebral blood flow and metabolism.” Official Journal of the International Society of Cerebral Blood Flow and Metabolism, 2011;31(11):2218-30. Epub 2011/06/16.
  60. Khanna S, Heigel M, Weist J, Gnyawali S, Teplitsky S, Roy S, et al. “Excessive alpha-tocopherol exacerbates microglial activation and brain injury caused by acute ischemic stroke.” Faseb J. 2014. Epub 2014/11/21.
  61. Tomeo AC, Geller M, Watkins TR, Gapor A, Bierenbaum ML. “Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis.” Lipids, 1995 Dec;30(12):1179-83.
  62. Kooyenga DK, Watson TR, Geller M, Bierenbaum M. “Antioxidants modulate the course of carotid atherosclerosis: A four-year report.” In: Nesaretnam K, Packer L, editors. Micronutrients and Health, Illinois: AOCS Press; 2001. p. 366-75.
  63. Newaz MA, Nawal NN. “Effect of gamma-tocotrienol on blood pressure, lipid peroxidation and total antioxidant status in spontaneously hypertensive rats (SHR).” Clinical and Experimental Hypertension, 1999;21(8):1297-313.
  64. Newaz MA, Yousefipour Z, Nawal N, Adeeb N. “Nitric oxide synthase activity in blood vessels of spontaneously hypertensive rats: antioxidant protection by gamma-tocotrienol.” Journal of Physiology and Pharmacology, 2003;54(3):319-27.
  65. Haleagrahara N, Swaminathan M, Chakravarthi S, Radhakrishnan A. “Therapeutic Efficacy of Vitamin E delta-Tocotrienol in Collagen-Induced Rat Model of Arthritis.” BioMed Research International, 2014;2014:539540. Epub 2014/08/13.
  66. Abdul Nasir NA, Agarwal R, Sheikh Abdul Kadir SH, Vasudevan S, Tripathy M, Iezhitsa I, et al. “Reduction of oxidative-nitrosative stress underlies anticataract effect of topically applied tocotrienol in streptozotocin-induced diabetic rats.” PLOS One, 2017;12(3):e0174542. Epub 2017/03/30.
  67. Abdul Nasir NA, Agarwal R, Vasudevan S, Tripathy M, Alyautdin R, Ismail NM. “Effects of Topically Applied Tocotrienol on Cataractogenesis and Lens Redox Status in galactosemic rats.” Molecular Vision, 2014 Jun 12;20:822-35. eCollection 2014.
  68. Shibata, A., et al. “Tumor anti-angiogenic effect and mechanism of action of delta-tocotrienol.” Biochemical Pharmacology, 2008. 76(3): p. 330-9.
  69. Pierpaoli E, Orlando F, Cirioni O, Simonetti O, Giacometti A, Provinciali M. “Supplementation with tocotrienols from Bixa orellana improves the in vivo efficacy of daptomycin against methicillin-resistant Staphylococcus aureus in a mouse model of infected wound.” Phytomedicine, 2017;36:50-3. Epub 2017/11/22.
  70. Kagan VE, Serbinova EA, Forte T, Scita G, Packer L. “Recycling of vitamin E in human low density lipoproteins.” Journal of Lipid Research, 1992;33(3):385-97. Epub 1992/03/01.
  71. Kagan V, Witt E, Goldman R, Scita G, Packer L. “Ultraviolet light-induced generation of vitamin E radicals and their recycling. A possible photosensitizing effect of vitamin E in skin.” Free Radical Research Communications, 1992;16(1):51-64. Epub 1992/01/01.
  72. Montagnani Marelli M, Marzagalli M, Moretti RM, Beretta G, Casati L, Comitato R, et al. “Vitamin E delta-tocotrienol triggers endoplasmic reticulum stress-mediated apoptosis in human melanoma cells.” Scientific Reports, 2016;6:30502. Epub 2016/07/28.
  73. Fernandes NV, Guntipalli PK, Mo H. “d-delta-Tocotrienol-mediated cell cycle arrest and apoptosis in human melanoma cells.” Anticancer Research, 30(12):4937-44.
  74. McAnally JA, Gupta J, Sodhani S, Bravo L, Mo H. “Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.” Experimental Biology and Medicine (Maywood), 2007 Apr;232(4):523-31.
  75. Fuchs J, Weber S, Podda M, Groth N, Herrling T, Packer L, et al. “HPLC analysis of vitamin E isoforms in human epidermis: correlation with minimal erythema dose and free radical scavenging activity.” Free Radical Biological Medicine, 2003;34(3):330-6. Epub 2003/01/25.
  76. Traber, M. G., M. Podda, et al. (1997). “Diet-derived and topically applied tocotrienols accumulate in skin and protect the tissue against ultraviolet light-induced oxidative stress.” Asia Pacific Journal of Clinical Nutrition, 6(1): 63-67.
  77. Michihara, A., Morita, S., Hirokawa, Y., Ago, K., & Tsuji, H. (2009). “Delta-tocotrienol causes decrease of melanin content in mouse melanoma cells.” Journal of Health Sciences, 55(2), 314-318.
  78. Musalmah M, Nizrana MY, Fairuz AH, NoorAini AH, Azian AL, Gapor MT, et al. “Comparative effects of palm vitamin E and alpha-tocopherol on healing and wound tissue antioxidant enzyme levels in diabetic rats.” Lipids, 2005;40(6):575-80. Epub 2005/09/10.
  79. Yap, W. N., N. Zaiden, et al. (2010). “Gamma- and delta-tocotrienols inhibit skin melanin synthesis by suppressing constitutive and UV-induced tyrosinase activation.” Pigment Cell & Melanoma Research, 23(5): 688-692.
  80. Institute, A.F.R.R. Radiation Countermeasures. 2011 6/14/2011; Available from:
  81. Kulkarni, S., et al. “Gamma-tocotrienol protects hematopoietic stem and progenitor cells in mice after total-body irradiation.” Radiat Research, 2010. 173(6): p. 738-47.
  82. Li, X.H., et al. “Delta-tocotrienol protects mouse and human hematopoietic progenitors from gamma-irradiation through extracellular signal-regulated kinase/mammalian target of rapamycin signaling.” Haematologica, 95(12): p. 1996-2004.
  83. Winkler-Moser JK, Bakota EL, Hwang HS. “Stability and Antioxidant Activity of Annatto (Bixa orellana L.) Tocotrienols During Frying and in Fried Tortilla Chips.” J Food Science and Technology, 2018;83(2):266-74. Epub 2018/01/18.
  84. Zou L, Akoh CC. “Antioxidant activities of annatto and palm tocotrienol-rich fractions in fish oil and structured lipid-based infant formula emulsion.” Food Chemistry, 2015;168:504-11. Epub 2014/08/31.
  85. Tan B, Mueller AM. “Tocotrienols in Cardiometabolic Diseases.” In: Watson R, Preedy V, editors. Tocotrienols: Vitamin E beyond Tocopherol: AOCS/CRC Press; 2008. p. 257-73.

Start typing and press Enter to search